Decision support tool helps City of Hope docs find answers quicker

Register now

City of Hope has adopted an evidence-based clinical decision support platform to aid oncologists in selecting optimal precision medicine treatments.

The Duarte, Calif.-based organization, which is an independent cancer research and treatment provider, is moving to the approach to find best treatments for each patient at the point of care.

The platform is Trapelo from software vendor Intervention Insights, which also offers order management and results reporting for molecular testing, appropriate workflows and collaboration between providers, laboratories and insurers.

Additional functionality includes a database of all genes, targeted agents and published evidence to aid oncologists in determining what should be tested and for which patients.

Also See: 5 ways clinical decision support can address current provider challenges

Oncologists also can order tests from the labs they use and have the results converted into standardized and actionable reports. For example, treatment options can be ranked according to levels of evidence, which helps clinicians make faster and better informed choices.

“As a leader in precision medicine, we at City of Hope understand that the space is changing rapidly and it is important that our physicians stay ahead of the changes,” says Michael Caligiuri, MD, president. “Trapelo will allow us to standardize and ensure the latest clinical evidence in the use of precision medicine is built into our workflows. It also will allow us to use our own protocols and identify patients for our clinical trials.”

City of Hope also expects the supporting technologies to help demonstrate new ways to use precision medicine at the point of care. The decision support also will assist in determining the most appropriate use of molecular testing while complying with the medical insurance policies of each patient.

For reprint and licensing requests for this article, click here.